Integrative analysis of mRNA and miRNA array data reveals the suppression of retinoic acid pathway in regulatory T cells of Graves' disease.

CONTEXT It is well known that regulatory T cells (Tregs) are abnormal in Graves' disease (GD) and play crucial roles in the breakdown of immune tolerance and GD development. However, there are controversies about whether the quantity and/or function of Tregs is aberrant in GD. The molecular mechanism of Tregs abnormality and its effects on GD development was still unclear, until now. OBJECTIVE MiRNAs play important roles in the function and development of the immune system including Tregs. To reveal the Tregs abnormality and its molecular mechanism in GD, we systematically studied the quantity and immunosuppressive function as well as the differential expression profiles of miRNA and mRNA of Tregs in newly diagnosed patients with GD using TaqMan miRNA array and mRNA microarray. RESULTS Our results showed that the quantity and immunosuppressive function of Tregs in initial patients with GD was significantly decreased. More importantly, the retinoic acid (RA) pathway was markedly suppressed and its agonist, all-trans retinoic acid, could notably improve the quantity and immunosuppressive function of Tregs from patients with GD in vitro. In addition, many other pathways including protein ubiquitination and circadian rhythm were also significantly regulated in Tregs of GD. CONCLUSIONS This integrative study first revealed the expression profiles of mRNA/miRNA in Tregs of initial GD and RA pathway might play important roles in GD development. Our results implied that all-trans RA, which had been used for a long time in the clinical setting, had potential value in the treatment of GD and was worthy of additional study.

[1]  Hiroya Yamada,et al.  Circulating microRNAs in autoimmune thyroid diseases , 2014, Clinical endocrinology.

[2]  M. Schott,et al.  microRNA expressions in CD4+ and CD8+ T-cell subsets in autoimmune thyroid diseases. , 2014, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[3]  Joseph S. Takahashi,et al.  TH17 Cell Differentiation Is Regulated by the Circadian Clock , 2013, Science.

[4]  A. Levine,et al.  Impairment of regulatory T-cell function in autoimmune thyroid disease. , 2013, Thyroid : official journal of the American Thyroid Association.

[5]  B. Li,et al.  Ubiquitination signals critical to regulatory T cell development and function. , 2013, International immunopharmacology.

[6]  J. Ellis,et al.  Transient depletion of CD4+ CD25+ regulatory T cells results in multiple autoimmune diseases in wild‐type and B‐cell‐deficient NOD mice , 2013, Immunology.

[7]  S. Lemieux,et al.  Transcriptome sequencing of neonatal thymic epithelial cells , 2013, Scientific Reports.

[8]  M. Ostapczuk,et al.  MicroRNAs miR-146a1, miR-155_2, and miR-200a1 are regulated in autoimmune thyroid diseases. , 2012, Thyroid : official journal of the American Thyroid Association.

[9]  Z. Chen,et al.  How to manage acute promyelocytic leukemia , 2012, Leukemia.

[10]  H. Liu,et al.  Function of regulatory T-cells improved by dexamethasone in Graves' disease. , 2012, European journal of endocrinology.

[11]  G. Ning,et al.  Differential microRNA expression in peripheral blood mononuclear cells from Graves' disease patients. , 2012, The Journal of clinical endocrinology and metabolism.

[12]  J. Lafaille,et al.  Induced CD4+Foxp3+ regulatory T cells in immune tolerance. , 2012, Annual review of immunology.

[13]  R. Caspi,et al.  A New Look at Immune Privilege of the Eye: Dual Role for the Vision-Related Molecule Retinoic Acid , 2011, The Journal of Immunology.

[14]  Y. Belkaid,et al.  The role of retinoic acid in tolerance and immunity. , 2011, Immunity.

[15]  G. Ning,et al.  Impairment of Regulatory Capacity of CD4+CD25+ Regulatory T Cells Mediated by Dendritic Cell Polarization and Hyperthyroidism in Graves’ Disease , 2011, The Journal of Immunology.

[16]  B. Falini,et al.  Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. , 2011, Blood.

[17]  Sihua Wang,et al.  Retinoic acid attenuates acute heart rejection by increasing regulatory T cell and repressing differentiation of Th17 cell in the presence of TGF‐β , 2010, Transplant international : official journal of the European Society for Organ Transplantation.

[18]  E. Granieri,et al.  Altered miRNA expression in T regulatory cells in course of multiple sclerosis , 2010, Journal of Neuroimmunology.

[19]  Jiajun Zhao,et al.  Identification of outer membrane porin f protein of Yersinia enterocolitica recognized by antithyrotopin receptor antibodies in Graves' disease and determination of its epitope using mass spectrometry and bioinformatics tools. , 2010, The Journal of clinical endocrinology and metabolism.

[20]  R. DePinho,et al.  Transcription factors Foxo3a and Foxo1 couple the E3 ligase Cbl-b to the induction of Foxp3 expression in induced regulatory T cells , 2010, The Journal of experimental medicine.

[21]  K. Kretschmer,et al.  Retinoic acid can enhance conversion of naive into regulatory T cells independently of secreted cytokines , 2009, The Journal of experimental medicine.

[22]  Cutting Edge: The Foxp3 Target miR-155 Contributes to the Development of Regulatory T Cells1 , 2009, The Journal of Immunology.

[23]  C. Burge,et al.  Most mammalian mRNAs are conserved targets of microRNAs. , 2008, Genome research.

[24]  Hilde Cheroutre,et al.  Reciprocal TH17 and Regulatory T Cell Differentiation Mediated by Retinoic Acid , 2007, Science.

[25]  C. Stephensen,et al.  Diets rich in polyphenols and vitamin A inhibit the development of type I autoimmune diabetes in nonobese diabetic mice. , 2007, The Journal of nutrition.

[26]  Y. Wan,et al.  Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression , 2007, Nature.

[27]  M. Osanai,et al.  Cellular Retinoic Acid Bioavailability Determines Epithelial Integrity: Role of Retinoic Acid Receptor α Agonists in Colitis , 2007, Molecular Pharmacology.

[28]  L. Wartofsky,et al.  Graves' disease. , 2007, The Journal of clinical endocrinology and metabolism.

[29]  F. J. Livesey,et al.  A role for Dicer in immune regulation , 2006, The Journal of experimental medicine.

[30]  F. Sánchez‐Madrid,et al.  Regulatory T cells in human autoimmune thyroid disease. , 2006, The Journal of clinical endocrinology and metabolism.

[31]  P. Purushottamachar,et al.  Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. , 2006, Bioorganic & medicinal chemistry.

[32]  T. E. Hinds.  Diseases , 2021, Modeling Biological Systems.

[33]  Anton J. Enright,et al.  Correction: Human MicroRNA Targets , 2005, PLoS Biology.

[34]  Anton J. Enright,et al.  Human MicroRNA Targets , 2004, PLoS biology.

[35]  H. Kagechika,et al.  Effect of Synthetic Retinoid, TAC-101, on Experimental Autoimmune Disease , 2002, Pharmacology.

[36]  R. Reifen,et al.  Vitamin A deficiency exacerbates inflammation in a rat model of colitis through activation of nuclear factor-kappaB and collagen formation. , 2002, The Journal of nutrition.

[37]  M. Kitamura,et al.  Selective Roles of Retinoic Acid Receptor and Retinoid X Receptor in the Suppression of Apoptosis by All-trans-retinoic Acid* , 2001, The Journal of Biological Chemistry.

[38]  R. Warrell,et al.  Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. , 1992, Cancer research.